COVID-19 vaccination in immunocompromised patients
Clin Rheumatol
.
2021 Feb;40(2):797-798.
doi: 10.1007/s10067-020-05547-w.
Epub 2021 Jan 11.
Authors
Bhavin Sonani
1
,
Fawad Aslam
2
,
Amandeep Goyal
3
,
Janki Patel
4
,
Pankaj Bansal
5
Affiliations
1
Department of Internal Medicine, HSHS St John's Hospital, 800 E Carpenter St, Springfield, IL, 62769, USA.
2
Department of Rheumatology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.
3
Department of Cardiology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160, USA.
4
Department of Infectious Diseases, Mayo Clinic Health System, 1400 Bellinger Street, Eau Claire, WI, 54701, USA.
5
Department of Rheumatology, Mayo Clinic Health System, 1400 Bellinger Street, Eau Claire, WI, 54701, USA. bansal.pankaj@mayo.edu.
PMID:
33426632
PMCID:
PMC7797352
DOI:
10.1007/s10067-020-05547-w
No abstract available
Publication types
Letter
MeSH terms
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Clinical Trials as Topic
Humans
Immunocompromised Host / immunology*
Vaccination
Substances
COVID-19 Vaccines